CA3216267A1 - Compositions de mousse pour le traitement d'infections a clostridioides difficile - Google Patents

Compositions de mousse pour le traitement d'infections a clostridioides difficile Download PDF

Info

Publication number
CA3216267A1
CA3216267A1 CA3216267A CA3216267A CA3216267A1 CA 3216267 A1 CA3216267 A1 CA 3216267A1 CA 3216267 A CA3216267 A CA 3216267A CA 3216267 A CA3216267 A CA 3216267A CA 3216267 A1 CA3216267 A1 CA 3216267A1
Authority
CA
Canada
Prior art keywords
composition
infection
agents
patient
foam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216267A
Other languages
English (en)
Inventor
Glenn W. Laub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tdl Innovations LLC
Original Assignee
Tdl Innovations LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tdl Innovations LLC filed Critical Tdl Innovations LLC
Publication of CA3216267A1 publication Critical patent/CA3216267A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de compositions de mousse pour l'administration d'agents thérapeutiques au niveau du côlon d'un patient en ayant besoin. L'invention concerne également des compositions de mousse et des dispositifs pour administrer la composition au niveau du côlon. De plus, l'invention concerne des méthodes de traitement de C. difficile dans le côlon à l'aide des compositions de mousse.
CA3216267A 2021-04-22 2022-04-22 Compositions de mousse pour le traitement d'infections a clostridioides difficile Pending CA3216267A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178234P 2021-04-22 2021-04-22
US63/178,234 2021-04-22
PCT/US2022/025934 WO2022226300A1 (fr) 2021-04-22 2022-04-22 Compositions de mousse pour le traitement d'infections à clostridioides difficile

Publications (1)

Publication Number Publication Date
CA3216267A1 true CA3216267A1 (fr) 2022-10-27

Family

ID=83722632

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216267A Pending CA3216267A1 (fr) 2021-04-22 2022-04-22 Compositions de mousse pour le traitement d'infections a clostridioides difficile

Country Status (3)

Country Link
EP (1) EP4326233A1 (fr)
CA (1) CA3216267A1 (fr)
WO (1) WO2022226300A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539571B1 (fr) 2018-03-16 2023-05-31 Critical Innovations, LLC Systèmes et procédés relatifs à des applications médicales de formulations de polymère synthétique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053517A2 (fr) * 2008-10-29 2010-05-14 Aroian Raffi V Polythérapie pour combattre une résistance aux helminthes
US20160002278A1 (en) * 2013-03-08 2016-01-07 Cipla Limited Pharmaceutical Compositions for Rectal Administration
RU2757275C2 (ru) * 2016-12-16 2021-10-12 Ферринг Б.В. Композиции ректальной пены

Also Published As

Publication number Publication date
WO2022226300A1 (fr) 2022-10-27
EP4326233A1 (fr) 2024-02-28

Similar Documents

Publication Publication Date Title
AU2013246701B2 (en) Probiotic bacteria
CN101175474B (zh) 降低微生物污染的方法
JP5331487B2 (ja) リファキシム抗直腸機能不全製剤
Fry Colon preparation and surgical site infection
JP2009537547A (ja) 生物学的治療組成物およびその使用
JP2008533048A (ja) 耳の感染症の治療方法
Blanchaert et al. Fecal microbiota transplantation in ulcerative colitis
CN109414432B (zh) 抗微生物化合物及其使用方法
JPH06501937A (ja) 非炎症性及び非感染性腸障害の処置
CN113559264A (zh) 治疗包括乳房炎的微生物感染的方法
Sundara Rajan et al. Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis
Poth Historical development of intestinal antisepsis
CA3216267A1 (fr) Compositions de mousse pour le traitement d'infections a clostridioides difficile
BR112019016705A2 (pt) composições e métodos para tratar doença associada à permeabilidade do epitélio intestinal
Jin et al. Lactobacillus fermentum ZYL0401 attenuates lipopolysaccharide-induced hepatic TNF-α expression and liver injury via an IL-10-and PGE2-EP4-dependent mechanism
Marandi et al. Immunization against Vibrio cholerae, ETEC, and EHEC with chitosan nanoparticle containing LSC chimeric protein
van Baal et al. Association between probiotics and enteral nutrition in an experimental acute pancreatitis model in rats
KR101642537B1 (ko) 푸시드산나트륨을 사용하고 생체중합체를 혼입한 약용 푸시드산 크림 및 이의 제조 방법
Cao et al. Bacteria-based drug delivery for treating non-oncological diseases
Petrujkić et al. Ex vivo absorption of thymol and thymol-β-D-glucopyranoside in piglet everted jejunal segments
US20240358638A1 (en) Foam compositions for treating clostridioides difficile infections
Anderson Fusidic acid: new opportunities with an old antibiotic.
WO2020191076A1 (fr) Compositions et méthodes pour traiter des maladies et des troubles gastro-intestinaux
Kulchavenya Current therapy and surgery for urogenital tuberculosis
Paral et al. Perioperative intrapelvic hyaluronate application as prophylaxis against complications following rectal anastomotic dehiscence: An experimental study